A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-55years Receiving Either an Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A/Belgium/4217/2015 (H3N2)
Latest Information Update: 13 May 2026
At a glance
- Drugs Influenza virus vaccine live (Primary)
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms GERMINATE
Most Recent Events
- 20 Apr 2026 Max age changed 40 to 55 years.
- 20 Apr 2026 Planned End Date changed from 6 Jan 2026 to 31 Jul 2026.
- 20 Apr 2026 Planned primary completion date changed from 6 Jan 2026 to 31 Jul 2026.